• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Introduction to 4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide (CAS No. 2101198-69-8)

4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research due to its unique structural properties and potential biological activities. This compound, identified by the CAS number 2101198-69-8, belongs to the pyrazole class of molecules, which are known for their broad spectrum of biological interactions and therapeutic applications. Pyrazole derivatives have been extensively studied for their roles in drug development, particularly in the treatment of inflammatory diseases, infectious disorders, and certain types of cancer.

The molecular structure of 4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide consists of a pyrazole ring substituted with an amino group at the 4-position, an ethyl group at the 1-position, and a propyl group at the same position. This specific arrangement of functional groups contributes to the compound's reactivity and interaction with biological targets. The presence of both basic and acidic functional groups in its structure allows it to engage in various types of chemical interactions, making it a versatile scaffold for drug design.

In recent years, there has been a growing interest in developing novel therapeutic agents based on pyrazole derivatives due to their demonstrated efficacy and favorable pharmacokinetic profiles. One of the most compelling aspects of this class of compounds is their ability to modulate multiple biological pathways simultaneously. For instance, studies have shown that certain pyrazole derivatives can inhibit enzymes involved in inflammation and oxidative stress, which are key mechanisms underlying many chronic diseases.

Recent research has highlighted the potential of 4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide as a lead compound for further drug development. In vitro studies have demonstrated its ability to interact with various protein targets, including kinases and transcription factors, which are critical for cell signaling and regulation. These interactions suggest that the compound may have therapeutic potential in conditions such as cancer, where dysregulation of cell signaling pathways is a hallmark feature.

The synthesis of 4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. The process typically begins with the formation of the pyrazole core through condensation reactions between appropriate precursors. Subsequent functionalization steps introduce the amino, ethyl, and propyl groups at specific positions on the ring. Advanced synthetic techniques, such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, are often employed to achieve these transformations efficiently.

One of the key challenges in working with 4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide is its sensitivity to environmental conditions such as moisture and light. To maintain its stability during storage and handling, it is typically stored under inert atmospheres or protected by desiccants. These precautions are essential to prevent degradation and ensure that the compound retains its intended properties for subsequent applications.

The pharmacological profile of 4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide is still under active investigation, but preliminary findings suggest that it may exhibit anti-inflammatory, antimicrobial, and anticancer properties. For example, studies have shown that related pyrazole derivatives can inhibit the activity of enzymes such as COX (cyclooxygenase) and LOX (lipoxygenase), which are involved in producing pro-inflammatory mediators. Additionally, some derivatives have demonstrated efficacy in inhibiting the growth of tumor cells by disrupting key signaling pathways.

In conclusion,4-amino-N-ethyl-1-propyl-1H-pyrazole-5-carboxamide (CAS No. 2101198-69-8) represents a promising candidate for further exploration in pharmaceutical research. Its unique structural features and potential biological activities make it an attractive scaffold for developing new therapeutic agents. As research continues to uncover more about its pharmacological properties,this compound may play a significant role in addressing various medical challenges in the future.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)